{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:54:32Z","timestamp":1791125672434,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.<\/jats:p>","DOI":"10.1186\/1756-8722-6-55","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T12:14:32Z","timestamp":1375445672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy"],"prefix":"10.1186","volume":"6","author":[{"given":"Madhav","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate J","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishuo","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"issue":"21","key":"324_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999, 341 (21): 1565-1571. 10.1056\/NEJM199911183412102.","journal-title":"N Engl J Med"},{"issue":"3","key":"324_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006, 24 (3): 431-436. 10.1200\/JCO.2005.03.0221.","journal-title":"J Clin Oncol"},{"issue":"27","key":"324_CR3","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","volume":"24","author":"L Mileshkin","year":"2006","unstructured":"Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM: Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006, 24 (27): 4507-4514. 10.1200\/JCO.2006.05.6689.","journal-title":"J Clin Oncol"},{"issue":"8","key":"324_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011, 29 (8): 986-993. 10.1200\/JCO.2010.31.6844.","journal-title":"J Clin Oncol"},{"issue":"2","key":"324_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/157489207780832478","volume":"2","author":"JB Aragon-Ching","year":"2007","unstructured":"Aragon-Ching JB, Li H, Gardner ER, Figg WD: Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov. 2007, 2 (2): 167-174.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"4","key":"324_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004, 4 (4): 314-322. 10.1038\/nrc1323.","journal-title":"Nat Rev Cancer"},{"issue":"30","key":"324_CR7","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008, 26 (30): 4952-4957. 10.1200\/JCO.2007.15.3429.","journal-title":"J Clin Oncol"},{"issue":"7","key":"324_CR8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P: An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011, 22 (7): 1622-1627. 10.1093\/annonc\/mdq626.","journal-title":"Ann Oncol"},{"issue":"32","key":"324_CR9","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009, 27 (32): 5404-5409. 10.1200\/JCO.2008.21.1169.","journal-title":"J Clin Oncol"},{"issue":"9","key":"324_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","volume":"26","author":"AA Chanan-Khan","year":"2008","unstructured":"Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008, 26 (9): 1544-1552. 10.1200\/JCO.2007.14.5367.","journal-title":"J Clin Oncol"},{"issue":"7","key":"324_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","volume":"30","author":"AK Gandhi","year":"2006","unstructured":"Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI: Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006, 30 (7): 849-858. 10.1016\/j.leukres.2006.01.010.","journal-title":"Leuk Res"},{"issue":"12","key":"324_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","volume":"57","author":"D Zhu","year":"2008","unstructured":"Zhu D, Corral LG, Fleming YW, Stein B: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008, 57 (12): 1849-1859. 10.1007\/s00262-008-0512-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"324_CR13","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB: lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008, 14 (14): 4650-4657. 10.1158\/1078-0432.CCR-07-4405.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"324_CR14","first-page":"154-a","volume":"2006","author":"NM Reddy","year":"2006","unstructured":"Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS: he use of the immunomodulatory drug, lenalidomide (Revlimid(R)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. AACR Meeting Abstracts. 2006, 2006 (1): 154-a-","journal-title":"AACR Meeting Abstracts"},{"issue":"7","key":"324_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/10428190802005191","volume":"49","author":"S Vallet","year":"2008","unstructured":"Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC: Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008, 49 (7): 1238-1245. 10.1080\/10428190802005191.","journal-title":"Leuk Lymphoma"},{"issue":"1\u20132","key":"324_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D: Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005, 69 (1\u20132): 56-63.","journal-title":"Microvasc Res"},{"issue":"21","key":"324_CR17","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG: Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009, 114 (21): 4713-4720. 10.1182\/blood-2009-04-217687.","journal-title":"Blood"},{"issue":"5971","key":"324_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010, 327 (5971): 1345-1350. 10.1126\/science.1177319.","journal-title":"Science"},{"issue":"18","key":"324_CR19","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL: Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011, 118 (18): 4771-4779. 10.1182\/blood-2011-05-356063.","journal-title":"Blood"},{"issue":"8","key":"324_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63 (8): 803-843. 10.2165\/00003495-200363080-00005.","journal-title":"Drugs"},{"issue":"9","key":"324_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M: Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009, 84 (9): 553-559. 10.1002\/ajh.21468.","journal-title":"Am J Hematol"},{"issue":"16","key":"324_CR22","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","volume":"11","author":"FJ Hernandez-Ilizaliturri","year":"2005","unstructured":"Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005, 11 (16): 5984-5992. 10.1158\/1078-0432.CCR-05-0577.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"324_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008, 140 (1): 36-45.","journal-title":"Br J Haematol"},{"issue":"1","key":"324_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000257990","volume":"123","author":"SJ Richardson","year":"2010","unstructured":"Richardson SJ, Eve HE, Copplestone JA, Dyer MJ, Rule SAJ: Activity of thalidomide and lenalidomide in mantle cell lymphoma. Acta Haematol. 2010, 123 (1): 21-29. 10.1159\/000257990.","journal-title":"Acta Haematol"},{"issue":"2","key":"324_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","volume":"110","author":"LM Morton","year":"2007","unstructured":"Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ: Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007, 110 (2): 695-708. 10.1182\/blood-2006-11-051672.","journal-title":"Blood"},{"key":"324_CR26","volume-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations)","author":"N Howlader","year":"1975","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H: SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations). 1975, Bethesda: National Cancer Institute, MD, http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09\/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012, \u20132009 (Vintage 2009 Populations)"},{"key":"324_CR27","first-page":"220","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"N Harris","year":"2008","unstructured":"Harris N, Swerdlow S, Jaffe E, Ott G, Nathwani B, de Jong D, Yoshino T, Spagnolo D: Follicular lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008, 220-226."},{"issue":"5","key":"324_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/CCO.0b013e3282c9ad78","volume":"19","author":"PJ Bierman","year":"2007","unstructured":"Bierman PJ: Natural history of follicular grade 3 non-Hodgkin's lymphoma. Curr Opin Oncol. 2007, 19 (5): 433-437. 10.1097\/CCO.0b013e3282c9ad78.","journal-title":"Curr Opin Oncol"},{"issue":"21","key":"324_CR29","first-page":"901","volume":"120","author":"NH Fowler","year":"2012","unstructured":"Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M: Lenalidomide and Rituximab for untreated indolent Lymphoma: final results of a phase II study. ASH Annual Meeting Abstracts. 2012, 120 (21): 901-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"324_CR30","doi-asserted-by":"crossref","unstructured":"Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M: High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol. suppl; abstr 8030","DOI":"10.1200\/jco.2011.29.15_suppl.8030"},{"issue":"2","key":"324_CR31","first-page":"2766","volume":"120","author":"S Rawal","year":"2012","unstructured":"Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M: Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. ASH Annual Meeting Abstracts 2012. 2012, 120 (2): 2766-","journal-title":"ASH Annual Meeting Abstracts 2012"},{"key":"324_CR32","first-page":"186","volume":"22","author":"M Dutia","year":"2011","unstructured":"Dutia M, Deroock I, Reed-Pease C, Tuscano J: LENALIDOMIDE PLUS RITUXIMAB LEADS TO A HIGH RATE OF DURABLE RESPONSES IN PATIENTS WITH RELAPSED\/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA. Ann Oncol. 2011, 22: 186-186.","journal-title":"Ann Oncol"},{"key":"324_CR33","doi-asserted-by":"crossref","unstructured":"Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD: Alliance for clinical trials in oncology: CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. SCO Meeting Abstracts. 2012, 30 (15):","DOI":"10.1200\/jco.2012.30.15_suppl.8000"},{"key":"324_CR34","volume-title":"Leukemia","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B: Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia. 2013, 10.1038\/leu.2013.95. [Epub ahead of print]"},{"issue":"25","key":"324_CR35","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (25): 1937-1947. 10.1056\/NEJMoa012914.","journal-title":"N Engl J Med"},{"issue":"6769","key":"324_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403 (6769): 503-511. 10.1038\/35000501.","journal-title":"Nature"},{"key":"324_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW: Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011, 2011: 498-505. 10.1182\/asheducation-2011.1.498.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"27","key":"324_CR38","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010, 28 (27): 4184-4190. 10.1200\/JCO.2010.28.1618.","journal-title":"J Clin Oncol"},{"issue":"22","key":"324_CR39","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS: Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011, 117 (22): 5058-5066. 10.1002\/cncr.26135.","journal-title":"Cancer"},{"issue":"21","key":"324_CR40","first-page":"3287","volume":"120","author":"L-H Zhang","year":"2012","unstructured":"Zhang L-H, Kosek J, Wang M, Heise C, Schafer PH, Chopra R: Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression. ASH Annual Meeting Abstracts. 2012, 120 (21): 3287-","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"324_CR41","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011, 11 (6): 462-466. 10.1016\/j.clml.2011.02.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"324_CR42","first-page":"3668-","volume":"120","author":"NM Reddy","year":"2012","unstructured":"Reddy NM, Simons RM, Caldwell ME, Chen H, Jagasia M, Morgan DS, Park SI, Greer JP, Richards KL: A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following R-CHOP chemotherapy for patients with high risk diffuse large B-cell lymphoma. ASH Annual Meeting Abstracts. 2012, 120 (21): 3668--","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"324_CR43","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2011.165","volume":"25","author":"GS Nowakowski","year":"2011","unstructured":"Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM: Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011, 25 (12): 1877-1881. 10.1038\/leu.2011.165.","journal-title":"Leukemia"},{"issue":"21","key":"324_CR44","first-page":"689","volume":"120","author":"GS Nowakowski","year":"2012","unstructured":"Nowakowski GS, LaPlant BR, Reeder C, Foran JM, Porrata LF, Macon WR, Johnston PB, Rivera CE, Habermann TM, Inwards DJ: Combination of Lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-Cell lymphomas - a phase II study. ASH Annual Meeting Abstracts. 2012, 120 (21): 689-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"324_CR45","first-page":"532","volume-title":"Hematology Am Soc Hematol Educ Program","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Burack WR: The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program. 2009, 532-541."},{"issue":"23","key":"324_CR46","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984, 311 (23): 1471-1475. 10.1056\/NEJM198412063112303.","journal-title":"N Engl J Med"},{"issue":"3","key":"324_CR47","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","volume":"80","author":"T Yano","year":"1992","unstructured":"Yano T, Jaffe ES, Longo DL, Raffeld M: MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992, 80 (3): 758-767.","journal-title":"Blood"},{"issue":"32","key":"324_CR48","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008, 26 (32): 5165-5169. 10.1200\/JCO.2008.16.0283.","journal-title":"J Clin Oncol"},{"issue":"4","key":"324_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","volume":"154","author":"MS Czuczman","year":"2011","unstructured":"Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB: The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011, 154 (4): 477-481. 10.1111\/j.1365-2141.2011.08781.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"324_CR50","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","volume":"67","author":"D Verhelle","year":"2007","unstructured":"Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007, 67 (2): 746-755. 10.1158\/0008-5472.CAN-06-2317.","journal-title":"Cancer Res"},{"issue":"11","key":"324_CR51","first-page":"2616","volume":"112","author":"S Gaidarova","year":"2008","unstructured":"Gaidarova S, Corral LG, Gleizer E, Young D, Brady H, Bennett B, Lopez-Girona A: Lenalidomide Enhances Anti-Tumor Effect of {gamma}{delta} T Cells against Mantle Cell Lymphoma. ASH Annual Meeting Abstracts. 2008, 112 (11): 2616-","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"324_CR52","first-page":"2612","volume":"112","author":"L-H Zhang","year":"2008","unstructured":"Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B: Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression. ASH Annual Meeting Abstracts. 2008, 112 (11): 2612-","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18","key":"324_CR53","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","volume":"69","author":"L Escoubet-Lozach","year":"2009","unstructured":"Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D: Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009, 69 (18): 7347-7356. 10.1158\/0008-5472.CAN-08-4898.","journal-title":"Cancer Res"},{"issue":"22","key":"324_CR54","first-page":"1687","volume":"114","author":"S Gaidarova","year":"2009","unstructured":"Gaidarova S, Corral LG, Glezer E, Schafer PH, Lopez-Girona A: reatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing. ASH Annual Meeting Abstracts. 2009, 114 (22): 1687-","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"22","key":"324_CR55","first-page":"3723","volume":"114","author":"AK Gandhi","year":"2009","unstructured":"Gandhi AK, Kang J, Capone L, Shafarenko M, Schafer PH: Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: an in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells. ASH Annual Meeting Abstracts. 2009, 114 (22): 3723-","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"324_CR56","first-page":"2845","volume":"116","author":"S Gaidarova","year":"2010","unstructured":"Gaidarova S, Mendy D, Heise C, Aukerman SL, Daniel T, Chopra R, Lopez-Girona A: Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells. ASH Annual Meeting Abstracts. 2010, 116 (21): 2845-","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:16:00Z","timestamp":1715814960000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-55","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]},"assertion":[{"value":"16 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}